Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study
Edward R. Cachay, Michael R. Peterson, Miguel Goicoechea, William C. Mathews
Journal of Advances in Medicine and Medical Research · pp. 346–355 · Published 23 Aug 2011
10.9734/BJMMR/2011/554Abstract
Aims: To describe: 1) our cohort of patients diagnosed with NCPH in a HIV academic clinic in North America, and 2) longitudinal follow-up and outcomes of patients following NCPH diagnosis. Study design: Retrospective case series Place and Duration of Study: Owen clinic, University of California, San Diego, United States, between October 1990 and December 2010. Methodology: We describe a cohort of patients diagnosed with NCPH in a HIV academic clinic with emphasis on their follow-up and outcomes after NCPH diagnosis. Results: During the study period, eight HIV-infected men were diagnosed with NCPH. All patients were exposed to Didanosine (ddI) for a median of 37 months. One patient died soon after NCPH diagnosis due to a condition unrelated to NCPH. The other seven patients have received B-blocker therapy and annual esophago-gastro-duodenectomy screenings with banding of esophageal varices when indicated and remain still alive. Three patients were on ddI at the time of NCPH diagnosis. In one patient ddI was discontinued shortly after NCPH diagnosis. The other two patients continued to use ddI after NCPH diagnosis and developed recurrent upper gastrointestinal bleeding in the subsequent 2 years, requiring revascularization interventions. The four patients that were already off ddI at the time of NCPH diagnosis have been followed for a median of 6 years. These four patients remained minimally symptomatic for up to 16 years of follow-up from NCPH diagnosis. Conclusion: When ddI was discontinued before portal hypertension was clinically apparent the progression of NCPH appeared to subside without major clinical complications.
References (21)
- 1 Problems of Spectrum and Bias in Evaluating the Efficacy of Diagnostic Tests [DOI]
- 2 Association of Noncirrhotic Portal Hypertension in HIV‐Infected Persons and Antiretroviral Therapy with Didanosine: A Nested Case‐Control Study [DOI]
- 3 Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings [DOI]
- 4 Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs [DOI]
- 5 Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients [DOI]
- 6 Hepatoportal Sclerosis as a Cause of Noncirrhotic Portal Hypertension in Patients With HIV [DOI]
- 7 Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy [DOI]
- 8 Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome [DOI]
- 9 Noncirrhotic Portal Hypertension in Patients With Human Immunodeficiency Virus–1 Infection [DOI]
- 10 Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients [DOI]
- 11 The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: A case control study [DOI]
- 12 Noncirrhotic portal hypertension: Another cause of liver disease in HIV patients [DOI]
- 13 Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Case Control Evaluation and Review of the Literature [DOI]
- 14 Nodular regenerative hyperplasia of liver as a consequence of ART [DOI]
- 15 Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? [DOI]
- 16 Noncirrhotic portal hypertension in HIV infection [DOI]
- 17 Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients [DOI]
- 18 Non-cirrhotic Intrahepatic Portal Hypertension: A Long Term Follow-up Study [DOI]
- 19 Response to Mallet et al., ‘Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients’ [DOI]
- 20 Abacavir and increased risk of myocardial infarction [DOI]
- 21 Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis [DOI]
Cited by 50
Gómez Alonso M, Goñi Esarte S, Bolado Concejo F · Gastroenterol Hepatol · 2017
Vilarinho S, Sari S, Yilmaz G · Hepatology · 2016
Turon F, Silva-Junior G, Hernandez-Gea V · Gastroenterol Hepatol · 2015
Acharya C, Dharel N, Sterling RK. · Clin Liver Dis · 2015
Goel A, Elias JE, Eapen CE · J Clin Exp Hepatol · 2014
Sood A, Castrejón M, Saab S. · World J Hepatol · 2014
Bhamidimarri KR, Schiff E. · Clin Liver Dis · 2013
Khanna R, Sarin SK. · J Hepatol · 2014
Showing 18 of 50 known citations — external sources report more than can currently be individually listed.
Related research
- Advancing Exclusive Breastfeeding among HIV-Positive Mothers in Low Resource Settings — shares topic coverage
- Seroprevalence of HIV, HBV and HCV among Prisoners in Sokoto, Nigeria — shares topic coverage
- Knowledge, Attitude and Utilization of HIV Post-Exposure Prophylaxis among Health Care Workers at HIV Treatment Centers in Port-Harcourt Metropolis — shares topic coverage
- Outcome of Prevention of Mother to Child Transmission (PMTCT) of HIV Services at the University of Port Harcourt Teaching Hospital (UPTH), Port Harcourt, Nigeria — shares topic coverage
- Pattern of Otorhinolaryngological Disorders in HIV Positive Paediatric Patients at the University of Port Harcourt Teaching Hospital (UPTH) — shares topic coverage
Article metrics
Real usage data collected on this platform.
10
Page views
0
PDF downloads
0
Outbound clicks
50
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.